1-19-2024: Kyoto, Japan: The anti-osteosarcoma chemotherapy mab, anlotinib, is suffering from drug resistance. "Tocilizumab hindered anlotinib-resistant osteosarcoma cell progression" https://t.co/HLvBJa12qy https://t.co/h3qlIRHXiE https://t.co/rGJBJzegvL
Here are the remaining 20 head researchers of Italy's 38 pro-Actemra COVID-19 studies: Masotti2, Mastroianni, Melegari, Menzella, Mikulska, Milic, Montini, Mussini, Perrone, Potere2, Rossotti, Russo, Salvati, Sciascia, Signore, Toniati, Vecchio, Vivarelli
6-14-2022: Jalisco, México: The anti-cancer drug, Actemra (tocilizumab), was called in to slow down the progression of metastatic prostate cancer in vitro: https://t.co/rGJBJyW7hD https://t.co/h3qlIRpO4w https://t.co/HLvBJ9ITcq https://t.co/yOXZ5Lg4Ec ht
3-9-2021: Surgeons warn that if they find evidence that your cancer has already spread to any bone, they will call off your planned cancer surgery. In a study just released today from Bologna, Italy, the bone density-improving drug, Actemra, was called in